SOURCE-LINKED STUDY SUMMARY
Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial.
Full paper summarizedQuality not appraised
- What was studied
- SUNRISE-1 compared the orexin antagonist lemborexant with placebo and extended-release zolpidem for objectively measured insomnia outcomes.
- Who / model studied
- Adults aged 55 and older had insomnia characterized by sleep-maintenance difficulty confirmed by history, diary and polysomnography.
- Studied dose & schedule
- At bedtime for one month, participants received placebo, zolpidem ER 6.25 mg, or lemborexant 5 or 10 mg.
- What the study found
- At the end of treatment, both doses improved sleep onset and efficiency versus placebo and reduced second-half wake time versus zolpidem.
- Limitations & context
- This was a short trial in older, mostly female adults using extended-release zolpidem as the active comparator. Six serious events occurred; none was treatment-related.
Read summary source ↗ · Prepared 10/6/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: full paper. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1001/jamanetworkopen.2019.18254